A Phase I Study of Oral BGJ398 in Asian Patients With Advanced Solid Tumor Having Alterations of the FGF-R Pathway

Trial Profile

A Phase I Study of Oral BGJ398 in Asian Patients With Advanced Solid Tumor Having Alterations of the FGF-R Pathway

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs Infigratinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 19 Jul 2017 Planned End Date changed from 12 Jun 2017 to 7 Dec 2017.
    • 19 Jul 2017 Planned primary completion date changed from 12 Jun 2017 to 7 Dec 2017.
    • 19 Oct 2016 Planned End Date changed from 1 Dec 2018 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top